

# Jos Beijnen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7237587/publications.pdf>

Version: 2024-02-01

136  
papers

5,385  
citations

101384

36  
h-index

91712

69  
g-index

138  
all docs

138  
docs citations

138  
times ranked

6757  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonlinear partial differential equations and applications: The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15649-15654.	3.3	759
2	Upfront Genotyping of <i>DPYD</i> to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. Journal of Clinical Oncology, 2016, 34, 227-234.	0.8	279
3	Clinical relevance of <i>DPYD</i> variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncology, The, 2015, 16, 1639-1650.	5.1	277
4	<i>DPYD</i> genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncology, The, 2018, 19, 1459-1467.	5.1	238
5	Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. Journal of Clinical Investigation, 2007, 117, 3583-3592.	3.9	210
6	Coadministration of Cyclosporine Strongly Enhances the Oral Bioavailability of Docetaxel. Journal of Clinical Oncology, 2001, 19, 1160-1166.	0.8	202
7	Are Adverse Events of Nevirapine and Efavirenz Related to Plasma Concentrations?. Antiviral Therapy, 2005, 10, 489-498.	0.6	135
8	Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. International Journal of Cancer, 2014, 134, 1484-1494.	2.3	127
9	Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacology Research and Perspectives, 2015, 3, e00131.	1.1	127
10	Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel. Clinical Cancer Research, 2006, 12, 5786-5793.	3.2	115
11	Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview. Oncologist, 2002, 7, 516-530.	1.9	107
12	ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy. Clinical Cancer Research, 2014, 20, 2703-2713.	3.2	105
13	Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treatment Reviews, 2015, 41, 412-422.	3.4	103
14	Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). International Journal of Pharmaceutics, 2011, 420, 244-250.	2.6	92
15	Improved Brain Penetration and Antitumor Efficacy of Temozolomide by Inhibition of ABCB1 and ABCG2. Neoplasia, 2018, 20, 710-720.	2.3	84
16	Phase I and Pharmacokinetic Study of Oral Paclitaxel. Journal of Clinical Oncology, 2000, 18, 2468-2475.	0.8	83
17	Nevirapine and Efavirenz Pharmacokinetics and Covariate Analysis in the 2Nn Study. Antiviral Therapy, 2005, 10, 145-155.	0.6	80
18	The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treatment Reviews, 2015, 41, 859-867.	3.4	79

#	ARTICLE	IF	CITATIONS
19	Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity – Ready for clinical practice?. <i>Cancer Treatment Reviews</i> , 2016, 50, 23-34.	3.4	76
20	A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy. <i>European Journal of Cancer</i> , 2019, 107, 60-67.	1.3	65
21	A flexed posture in elderly patients is associated with impairments in postural control during walking. <i>Gait and Posture</i> , 2014, 39, 767-772.	0.6	62
22	Systematic Review of Biomarkers To Monitor Therapeutic Response in Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1-14.	1.4	62
23	Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). <i>Pharmacological Research</i> , 2015, 102, 200-207.	3.1	59
24	EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors. <i>Neuro-Oncology</i> , 2016, 18, 855-862.	0.6	57
25	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). <i>Pharmaceutical Research</i> , 2015, 32, 2205-2216.	1.7	53
26	Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 5331-5345.	1.9	47
27	Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 128-134.	1.4	47
28	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. <i>Pharmacological Research</i> , 2017, 120, 43-50.	3.1	43
29	Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. <i>British Journal of Cancer</i> , 2015, 113, 396-402.	2.9	42
30	A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 2984-2990.	1.2	40
31	Pharmaceutical development of an oral tablet formulation containing a spray dried amorphous solid dispersion of docetaxel or paclitaxel. <i>International Journal of Pharmaceutics</i> , 2016, 511, 765-773.	2.6	40
32	Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care. <i>European Journal of Cancer</i> , 2016, 54, 120-130.	1.3	40
33	Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases. <i>Neurology</i> , 2020, 94, e521-e528.	1.5	40
34	Development and validation of a rapid and sensitive UPLC–MS/MS method for determination of uracil and dihydrouracil in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 126, 75-82.	1.4	39
35	Liquid chromatography–tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 118, 123-131.	1.4	39
36	Liquid chromatography–tandem mass spectrometric assay for the T790M mutant EGFR inhibitor osimertinib (AZD9291) in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1031, 80-85.	1.2	38

#	ARTICLE	IF	CITATIONS
37	Development and validation of a liquid chromatography-tandem mass spectrometry assay for nine oral anticancer drugs in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 174, 561-566.	1.4	38
38	Population Pharmacokinetic-Pharmacodynamic Analysis of Trastuzumab-Associated Cardiotoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 126-132.	2.3	35
39	EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid. <i>Journal of Neuro-Oncology</i> , 2018, 137, 1-10.	1.4	33
40	P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450 3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. <i>International Journal of Cancer</i> , 2018, 143, 2029-2038.	2.3	32
41	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. <i>Pharmacological Research</i> , 2018, 129, 414-423.	3.1	31
42	Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 110, 58-66.	1.4	30
43	Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O <sup>6</sup> -desmethyl metabolites of erlotinib and gefitinib in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1033-1034, 390-398.	1.2	30
44	P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice. <i>Clinical Cancer Research</i> , 2014, 20, 3133-3145.	3.2	29
45	Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). <i>Pharmacological Research</i> , 2019, 146, 104297.	3.1	29
46	CD20 antigen imaging with 124I-rituximab PET/CT in patients with rheumatoid arthritis. <i>Human Antibodies</i> , 2011, 20, 29-35.	0.6	28
47	Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer. <i>Cancers</i> , 2016, 8, 6.	1.7	28
48	Improving the solubility of nilotinib through novel spray-dried solid dispersions. <i>International Journal of Pharmaceutics</i> , 2017, 529, 294-302.	2.6	28
49	Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1090, 14-21.	1.2	27
50	Recent developments in the chromatographic bioanalysis of approved kinase inhibitor drugs in oncology. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 130, 244-263.	1.4	26
51	Brain Accumulation of Ponatinib and Its Active Metabolite, <i>N</i> -Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2). <i>Molecular Pharmaceutics</i> , 2017, 14, 3258-3268.	2.3	25
52	P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability. <i>Pharmacological Research</i> , 2018, 137, 47-55.	3.1	25
53	Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 664-671.	1.1	24
54	A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir. <i>European Journal of Cancer</i> , 2017, 86, 217-225.	1.3	23

#	ARTICLE	IF	CITATIONS
55	PK/PD Model of Indisulam and Capecitabine: Interaction Causes Excessive Myelosuppression. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 829-839.	2.3	22
56	Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 374-385.	1.3	22
57	Crizotinib-induced fatal fulminant liver failure. <i>Lung Cancer</i> , 2016, 93, 17-19.	0.9	22
58	Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 161, 136-143.	1.4	22
59	Therapeutic drug monitoring of imatinib in patients with gastrointestinal stromal tumours – Results from daily clinical practice. <i>European Journal of Cancer</i> , 2020, 136, 140-148.	1.3	22
60	Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 61-70.	1.1	21
61	Solubility and bioavailability improvement of pazopanib hydrochloride. <i>International Journal of Pharmaceutics</i> , 2018, 544, 181-190.	2.6	21
62	Neoadjuvant Systemic Treatment of Primary Angiosarcoma. <i>Cancers</i> , 2020, 12, 2251.	1.7	20
63	Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective. <i>Clinical Breast Cancer</i> , 2015, 15, 241-244.	1.1	18
64	Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1012-1013, 118-123.	1.2	18
65	Relevance of Endoxifen Concentrations: Absence of Evidence Is Not Evidence of Absence. <i>Journal of Clinical Oncology</i> , 2019, 37, 1980-1981.	0.8	18
66	Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	17
67	Treatment Individualization in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 335-344.	1.0	17
68	Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy. <i>Breast</i> , 2018, 42, 38-40.	0.9	17
69	Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 136, 120-130.	2.0	17
70	Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1083, 204-208.	1.2	16
71	LC-MS/MS assay for the quantification of testosterone, dihydrotestosterone, androstenedione, cortisol and prednisone in plasma from castrated prostate cancer patients treated with abiraterone acetate or enzalutamide. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 170, 161-168.	1.4	16
72	Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 90, 7-14.	1.4	15

#	ARTICLE	IF	CITATIONS
73	<i>P</i>-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Brutonâ€™s Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. <i>Molecular Pharmaceutics</i> , 2018, 15, 5124-5134.	2.3	15
74	SELDI-TOF MS serum protein profiles in breast cancer: Assessment of robustness and validity. <i>Cancer Biomarkers</i> , 2006, 2, 235-248.	0.8	14
75	Disease Progression/Clinical Outcome Model for Castrationâ€™Resistant Prostate Cancer in Patients Treated With Eribulin. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 386-395.	1.3	14
76	OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. <i>British Journal of Pharmacology</i> , 2020, 177, 3060-3074.	2.7	14
77	Neutropenia and docetaxel exposure in metastatic castrationâ€™resistant prostate cancer patients: A metaâ€™analysis and evaluation of a clinical cohort. <i>Cancer Medicine</i> , 2019, 8, 1406-1415.	1.3	13
78	Skin tissue sample collection, sample homogenization, and analyte extraction strategies for liquid chromatographic mass spectrometry quantification of pharmaceutical compounds. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 191, 113590.	1.4	12
79	Extrahepatic metabolism of ibrutinib. <i>Investigational New Drugs</i> , 2021, 39, 1-14.	1.2	12
80	The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108984.	1.6	12
81	Liquid chromatographyâ€™tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1023-1024, 24-29.	1.2	11
82	An LCâ€™MS/MS method for quantification of the active abiraterone metabolite Î² (4)-abiraterone (D4A) in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1068-1069, 119-124.	1.2	11
83	Bioanalytical method for the simultaneous quantification of irinotecan and its active metabolite SN-38 in mouse plasma and tissue homogenates using HPLC-fluorescence. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1149, 122177.	1.2	11
84	Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer) Tj ETQqO 0 0 rgBT /Overlock 10 Tf 50	2.6	11
85	Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. <i>European Journal of Cancer</i> , 2020, 130, 32-38.	1.3	11
86	Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1174, 122718.	1.2	11
87	Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018, 1102-1103, 167-172.	1.2	10
88	Development and validation of LC-MS/MS methods for the quantification of the novel anticancer agent guadecitabine and its active metabolite Î²â€™decitabine in human plasma, whole blood and urine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1109, 132-141.	1.2	10
89	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. <i>International Journal of Pharmaceutics</i> , 2019, 556, 172-180.	2.6	10
90	P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). <i>International Journal of Pharmaceutics</i> , 2020, 573, 118842.	2.6	10

#	ARTICLE	IF	CITATIONS
91	Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 203, 114225.	1.4	10
92	Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1110-1111, 116-123.	1.2	9
93	Development, validation, and clinical application of a high-performance liquid chromatography-tandem mass spectrometry assay for the quantification of total intracellular $\beta$ -deoxythymine nucleotides and genomic DNA incorporated $\beta$ -deoxythymine and 5-methyl-2'-deoxycytidine. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 164, 16-26.	1.4	9
94	Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 207, 114402.	1.4	9
95	ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites. <i>Pharmacological Research</i> , 2022, 178, 105954.	3.1	9
96	Gastric Bypass May Promote Weight Loss in Overweight Partners. <i>Journal of the American Board of Family Medicine</i> , 2015, 28, 90-96.	0.8	8
97	Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1147, 122131.	1.2	8
98	Highly sensitive UPLC-MS/MS method for the quantification of paromomycin in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 185, 113245.	1.4	8
99	Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR mutant non-small cell lung cancer. <i>Clinical and Translational Science</i> , 2022, 15, 1916-1925.	1.5	8
100	Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1061-1062, 300-305.	1.2	7
101	Thermal stability study of crystalline and novel spray-dried amorphous nilotinib hydrochloride. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 148, 182-188.	1.4	7
102	Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e383-e386.	0.9	7
103	Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1144, 122098.	1.2	7
104	The pharmacokinetics of 124I-rituximab in patients with rheumatoid arthritis. <i>Human Antibodies</i> , 2011, 20, 7-14.	0.6	6
105	Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 190, 113516.	1.4	6
106	Cost-Effectiveness Assessment of Monitoring Abiraterone Levels in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Value in Health</i> , 2021, 24, 121-128.	0.1	6
107	ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1173-1182.	1.9	6
108	The development and validation of a high performance liquid chromatography method to determine the radiochemical purity of [ $^{177}\text{Lu}$ ]Lu-HA-DOTA-TATE in pharmaceutical preparations. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1171, 122605.	1.2	6

#	ARTICLE	IF	CITATIONS
109	ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib. <i>Pharmacological Research</i> , 2021, 172, 105850.	3.1	6
110	Chromatographic bioanalytical assays for targeted covalent kinase inhibitors and their metabolites. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1162, 122466.	1.2	6
111	ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. <i>Pharmaceutics</i> , 2021, 13, 1761.	2.0	6
112	Clinical Relevance: Drug-Drug Interactions, Pharmacokinetics, Pharmacodynamics, and Toxicity. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2021, 46, 747-880.		5
113	Clinical trial simulations in paediatric oncology: A feasibility study from the Innovative Therapies for Children with Cancer Consortium. <i>European Journal of Cancer</i> , 2017, 85, 78-85.	1.3	5
114	Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1122-1123, 78-82.	1.2	5
115	Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice. <i>Drugs and Aging</i> , 2019, 36, 379-385.	1.3	5
116	The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor miliciclib. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 159, 105740.	1.9	5
117	Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015, 107, 403-408.	1.4	4
118	A multi-gram-scale stereoselective synthesis of Z-endoxifen. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1352-1356.	1.0	4
119	Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. <i>Pharmaceutical Research</i> , 2019, 36, 181.	1.7	4
120	Bioanalysis of erlotinib, its O-demethylated metabolites OSI-413 and OSI-420, and other metabolites by liquid chromatography-tandem mass spectrometry with additional ion mobility identification. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1166, 122554.	1.2	4
121	ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability. <i>Pharmacological Research</i> , 2022, 178, 106137.	3.1	4
122	Novel Clinical Trial Designs for Innovative Therapies. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 212-216.	2.3	3
123	Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 205, 114319.	1.4	3
124	Optimized sample pre-treatment procedure for the simultaneous UPLC-MS/MS quantification of ipilimumab, nivolumab, and pembrolizumab in human serum. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2022, 1196, 123215.	1.2	3
125	The pharmacokinetics of <sup>131</sup> I-rituximab in a patient with CD20 positive Non-Hodgkin Lymphoma: Evaluation of the effect of radioiodination on the biological properties of rituximab. <i>Human Antibodies</i> , 2011, 20, 37-40.	0.6	2
126	Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantromium bromide (YM155) in mouse plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 92, 144-148.	1.4	2



#	ARTICLE	IF	CITATIONS
127	Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 929-937.	0.8	2
128	Population Pharmacokinetic Modelling to Support the Evaluation of Preclinical Pharmacokinetic Experiments with Lorlatinib. <i>Journal of Pharmaceutical Sciences</i> , 2022, 111, 495-504.	1.6	2
129	P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO). <i>Pharmaceuticals</i> , 2021, 14, 1087.	1.7	2
130	Development and validation of an LC-MS/MS assay for the quantification of cintirorgon (LYC-55716) in mouse plasma and tissue homogenates. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 207, 114421.	1.4	1
131	The Role of ABC Transporters at the Intestinal Barrier. , 0, , 385-409.		0
132	Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e893-e896.	0.9	0
133	Treatment of older patients with immune checkpoint inhibitors in routine clinical care as compared to inclusion in pivotal registration trials. <i>Journal of Geriatric Oncology</i> , 2020, 11, 529-532.	0.5	0
134	Quantitative LC-MS/MS analysis of 5-hydroxymethyl-2- $\beta$ -deoxyuridine to monitor the biological activity of J-binding protein. <i>Analytical Biochemistry</i> , 2020, 610, 113930.	1.1	0
135	Development and Validation of a Stability-indicating HPLC Method for the Analysis of Cabazitaxel in Jevtana <sup>®</sup> Concentrate-solvent Leftover Samples. <i>Current Pharmaceutical Analysis</i> , 2021, 17, 691-701.	0.3	0
136	Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 170, 197-207.	2.0	0